Due to scheduled maintenance work on our database systems, there may be short service disruptions on this website between 10:00 and 11:00 CEST on June 14th.

From Physiology and Pathology Research to Clinical Insights in Gastrointestinal Disorders

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 576

Special Issue Editors


E-Mail Website
Guest Editor
Department of Internal Medicine I Medical Semiotics I, Center for Advanced Research in Cardiovascular Pathology and Hemostaseology, “V Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
Interests: innovative diagnostic and therapeutical approaches in hepatic; biliary tree and pancreatic diseases; novelties in functional gastro-intestinal disorders; brain–gut axis; gut microbiota dysbiosis
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania
Interests: gut microbiome; infectious diseases; antimicrobial resistance; respiratory infections; opportunistic infections
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
1. Discipline of Pathophysiology, Department of Functional Sciences, “Victor Babeș” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
2. Institute for Cardiovascular Diseases of Timisoara, Clinic for Cardiovascular Surgery, Gh. Adam Street, No. 13A, 300310 Timisoara, Romania
3. Centre for Translational Research and Systems Medicine, “Victor Babeș” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
Interests: advancements in vascular physiology; inflammation and oxidative stress; minimally invasive vascular and cardiac surgical procedures

Special Issue Information

Dear Colleagues,

This Special Issue aims to emphasize the crucial relationship between physiology and pathology research achievements and the clinical approaches of patients to gastrointestinal disorders.

By exploring the underlying physiology and the pathology, this Special Issue will focus on key mechanisms and pathways related to cellular signaling, inflammation and their actors and oxidative stress, whilst also highlighting the importance of specific functions of the digestive tract—motility, secretion, nutrient absorption and its complex function—where the brain–gut interaction plays a vital role.

Other aspects related to cellular death encompass necrosis and apoptosis, cellular proliferation, and various vascular features of the digestive tract. However, the liver and pancreas will also be of great interest.

The gut microbiota, another key actor involved in human health—as well as in many organic and functional gastrointestinal disorders—will also be reviewed.

We aim for this Special Issue to increase our understanding of the concept “from bench to bedside”, contributing to new advances in how we view underlying mechanisms and resulting in the creation of innovative diagnostic and therapeutical tools that will become reliable assets in clinical practice.

Dr. Doina Georgescu
Dr. Felix Bratosin
Dr. Ana Lascu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cellular signaling
  • inflammation
  • oxidative stress
  • cellular death and proliferation
  • motility, digestion and absorption
  • vascular patterns
  • gut microbiota

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1772 KiB  
Article
Clinical Efficacy of Sodium Butyrate in Managing Pediatric Inflammatory Bowel Disease
by Adrian Goldiș, Radu Dragomir, Marina Adriana Mercioni, Diana Sirca, Christian Goldiș, Ileana Enatescu, Laura Olariu and Oana Belei
Life 2025, 15(6), 902; https://doi.org/10.3390/life15060902 - 31 May 2025
Viewed by 317
Abstract
Background: Few studies have evaluated the efficacy of butyric acid in treating children with inflammatory bowel disease (IBD). In children and adolescents with recently diagnosed IBD, the purpose of this research was to assess the efficacy of oral sodium butyrate (the product-patented, sustained [...] Read more.
Background: Few studies have evaluated the efficacy of butyric acid in treating children with inflammatory bowel disease (IBD). In children and adolescents with recently diagnosed IBD, the purpose of this research was to assess the efficacy of oral sodium butyrate (the product-patented, sustained and targeted-release form of butyrate MSB®) as an adjunct to conventional treatment. Methods: This trial was unicentric, prospective, randomized, and placebo-controlled. An amount of 150 mg sodium butyrate once a day (Group A), or a placebo (Group B) were randomly assigned to patients with ulcerative colitis or Crohn’s disease, aged 7–18 years, who were receiving conventional medication based on the severity of their conditions. Disease activity, C-reactive protein (CRP), and fecal calprotectin concentration differences between the two study groups at 12 weeks of the trial were the main outcomes. Results: With 44 patients in Group A and 44 in Group B, 88 individuals with initially active illness finished the research. Most patients experienced remission by week 12 of the study (36 patients in Group A with sodium butyrate, 81.82%; 21 patients in Group B with placebo, 47.73%). Between the two groups, a significant difference in disease activity was seen (p < 0.001). The sodium butyrate group appeared to have less systemic inflammation than the other group, as evidenced by the significantly lower CRP levels in Group A (18.14 ± 11.19 mg/L) compared to Group B (57.00 ± 33.28 mg/L) at 12 weeks (T2) (p < 0.001). No negative effects were recorded by any of the patients. Fecal calprotectin in Group A dropped much more after 12 weeks (T2) (p < 0.001), suggesting that the sodium butyrate group was better able to regulate intestinal inflammation. Conclusions: In newly diagnosed children and adolescents with IBD, a 12-week sodium butyrate supplementation did demonstrate effectiveness as an additional treatment. Full article
Show Figures

Figure 1

Back to TopTop